When thyroid hormone replacement is ineffective?

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 5, 2013, Pages 467-477

  Benvenga, Salvatore ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

thyrotropin; thyroxine malabsorption; thyroxine replacement therapy

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; THYROID HORMONE; THYROTROPIN;

BARIATRIC SURGERY; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; MALABSORPTION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; TABLET FORMULATION; THYROID GLAND; THYROTROPIN BLOOD LEVEL; TREATMENT FAILURE; TSH SECRETING CELL;

BARIATRIC SURGERY; CHEMISTRY, PHARMACEUTICAL; DIGESTIVE SYSTEM DISEASES; ENDPOINT DETERMINATION; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOTHYROIDISM; PATIENT COMPLIANCE; THYROID HORMONES; TREATMENT FAILURE;

EID: 84883656469     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000003     Document Type: Review

References (101)

1. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012; 22:1200-1235.
2. Gullo D, Latina A, Frasca F, et al. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS One 2011; 6:e22552.
3. Larsen PR, Davies TF. Hypothyroidism and thyroiditis. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams textbook of endocrinology, 10th ed Philadelphia: Saunders; 2005. pp. 423-455.
4. Wiersinga WM, Duntas L, Fadeyev V, et al. ETA 2012 guidelines: the use of L-T4+L-T3 in the treatment of hypothyroidism. Eur Thyroid J 2012; 1:55-71.
5. Grozinsky-Glasberg S, Fraser A, Nahshoni E, et al. Thyroxine- triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2006; 91:2592-2599. (Pubitemid 44024623)
6. Biondi B, Wartofky L. Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism? J Clin Endocrinol Metab 2012; 97:2256-2271.
7. Jonklaas J. Treatment of hypothyroidism. In: Braverman LE, Cooper DS, editors. Werner and Ingbar's The thyroid: a fundamental and clinical text, 10th ed Philadelphia: Wolters Kluwer, Lippincott Williams & Wilkins; 2013. pp. 611-628.
8. Hollowell JG, Staheling NW, Flanders WD, et al. Serum TSH, T4 and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489-499. (Pubitemid 34158210)
9. Vaisman F, Coeli CM, Ward LS, et al. How good is the levothyroxine replacement in primary hypothyroidism patients in Brazil? Data of a multicentre study. J Endocrinol Invest 2013; 36:485-488.
10. Vigário PD, Vaisman F, Coeli CM, et al. Inadequate levothyroxine replacement for primary hypothyroidism is associated with poor health-related quality of life: a Brazilian multicentre study. Endocrine 2013. [Epub ahead of print].
11. Koulouri O, Auldin MA, Agarwal R, et al. Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. Clin Endocrinol (Oxf) 2011; 74:744-749.
12. Morris JC. How do you approach the problem of TSH elevation in a patient on high-dose thyroid hormone replacement? Clin Endocrinol 2009; 70:671-673.
13. Ward LS. The difficult patient: drug interaction and the influence of concomitant diseases on the treatment of hypothyroidism. Arq Brasil Endocrinol Metab 2010; 54:435-442.
14. Gregoric E, Gregoric JA, Guarneri F, Benvenga S. Injections of Clostridium botulinum neurotoxin A may cause thyroid complications in predisposed persons based on molecular mimicry with thyroid autoantigens. Endocrine 2011; 39:41-47.
15. Benvenga S, Bartolone L, Squadrito S, et al. Delayed absorption of levothyroxine. Thyroid 1995; 5:249-253.
16. Almashraki N, Abdulnabee MZ, Sukalo M, et al. Johanson-Blizzard syndrome. World J Gastroenterol 2011; 17:4247-4250.
17. Despré s N, Grant AM. Antibody interference in thyroid assays: a potential for clinical misinformation. Clin Chem 1998; 44:440-458.
18. Ismail AA. Interference from endogenous antibodies in automated immunoassays: what the laboratorians need to know. J Clin Pathol 2009; 62:673-678.
19. Loh TP, Kao SL, Halsall DJ, et al. Macro-thyrotropin: a case report and review of the literature. J Clin Endocrinol Metab 2012; 97:1823-1828.
20. Suzuki Y, Takeshita E, Kano S, et al. Impaired intestinal absorption of thyroid hormone in a case of Hashimoto's disease with anti-T3 and anti-T4 antibody. Nihon Naibunpi Gakkai Zasshi 1982; 58:1487-1497. (Pubitemid 13088443)
21. Simard JF, Holmqvist M. Rheumatoid factor positivity in the general population. BMJ 2012; 345:e5841.
22. Cárdenas Roldán J, Amaya-Amaya J, Castellanos-de la Hoz J, et al. Autoimmune thyroid disease in rheumatoid arthritis: a global perspective. Arthritis 2012; ID 864907.
23. Pioro EP, Scheithauer BW, Laws ER Jr, et al. Combined thyrotroph and lactotroph cell hyperplasia simulating prolactin-secreting pituitary adenoma in long-standing primary hypothyroidism. Surg Neurol 1988; 29:218-226. (Pubitemid 18064481)
24. Cannavò S, Li Calzi L, Trimarchi F. Pituitary enlargement in postsurgical hypothyroidism misdiagnosed as thyrotroph neoplasia. Report of a case. Minerva Endocrinol 1989; 14:193-196.
25. Xu AJ, Li T. Pituitary hyperplasia secondary to primary hypothyroidism in children: report of 8 cases. Zhongguo Dang Dai Er Ke Za Zhi 2010; 12: 17-20.
26. JoshiAS,WoolfPD. Pituitary hyperplasia secondary to primary hypothyroidism: a case report and review of the literature. Pituitary 2005; 8:99-103.
27. Beck-Peccoz P, Persani L, Asteria C, et al. Thyrotropin-secreting pituitary tumors in hyper- and hypothyroidism. Acta Med Austriaca 1996; 23: 41-46. (Pubitemid 126443905)
28. Myers A, Hatanpaa KJ, Madden C, Lingvay I. Thyrotropin-secreting adenoma in a patient with primary hypothyroidism. Endocr Pract 2011; 17:e135-e139.
29. Losa M, Mortini P, Minelli R, Giovanelli M. Coexistence of TSH-secreting pituitary adenoma and autoimmune hypothyroidism. J Endocrinol Invest 2006; 29:555-559. (Pubitemid 44164898)
30. Langlois MF, Lamarche JB, Bellabarba D. Long-standing goiter and hypothyroidism: an unusual presentation of a TSH-secreting adenoma. Thyroid 1996; 6:329-335. (Pubitemid 26303140)
31. Idiculla JM, Beckett G, Statham PF, et al. Autoimmune hypothyroidism coexisting with a pituitary adenoma secreting thyroid-stimulating hormone, prolactin and alpha-subunit. Ann Clin Biochem 2001; 38:566-571. (Pubitemid 32846066)
32. Kienitz T, Quinckler M, Strasburger CJ, Ventz M. Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature. Eur J Endocrinol 2007; 157:39-46. (Pubitemid 47162564)
33. Onnestam L, Berinder K, Burman P, et al. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab 2013; 98:626-635.
34. Crilly M. Thyroxine adherence in primary hypothyroidism. Lancet 2004; 363:1558.
35. Crilly M, Esmail A. Randomised controlled trial of a hypothyroid educational booklet to improve thyroxine adherence. Br J Gen Pract 2005; 55:362-368. (Pubitemid 40585210)
36. López-Torres Hidalgo R, Carbajal de Lara JA, Grupo de Investigación del Colegio Oficial de Farmacé uticos de Albacete (GICOFAB). Levothyroxine therapy compliance. What can we do to improve it? Aten Primaria 2010; 44:438-439.
37. Kubota S, Fukata S, Matsuzuka F, et al. Successful management of a patient with pseudomalabsorption of levothyroxine. Int J Psychiatry Med 2003; 33:183-188. (Pubitemid 37151544)
38. Molines L, Fromont I, Morlet-Barla N, et al. L-thyroxine pseudomalabsorption: a factitious disease. Presse Med 2007; 36:1390-1394.
39. Bach-Huynh TG, Nayak B, Loh J, et al. Timing of levothyroxine administration affects serum thyrotropin concentrations. J Clin Endocrinol Metab 2009; 94:3905-3912.
40. Bolk N, Visser TJ, Nijman J, et al. Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Arch Intern Med 2010; 170:1996-2003.
41. Wenzel KW, Kirschsieper HE. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 1977; 26:1-8. (Pubitemid 8027634)
42. Wonsick C, Hays MT. Absorption of oral thyroxine. Endocrinologist 1995; 5:222-228.
43. Liel Y, Harman-Boehm I, Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. J Clin Endocrinol Metab 1996; 81:857-859. (Pubitemid 26055713)
44. Geatti O, Barkan A, Turrin D, et al. L-thyroxine malabsorption due to the injection of herbal remedies. Thyroidology 1993; 5:97-102.
45. Deiana L, Marini S, Mariotti S. Ingestion of large amounts of papaya fruit and impaired effectiveness of levothyroxine therapy. Endocr Pract 2012; 18:98-100.
46. Bell DS, Ovalle F. Use of soy protein supplement and resultant need for increased dose of levothyroxine. Endocr Pract 2001; 7:193-194. (Pubitemid 32514876)
47. Lilja JJ, Laitinen K, Neuvonen PJ. Effect of the grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol 2005; 60:337-341. (Pubitemid 41224144)
48. Benvenga S, Bartolone L, Pappalardo MA, et al. Altered intestinal absorption of levothyroxine caused by coffee. Thyroid 2008; 18:293-301. (Pubitemid 351415797)
49. Vita R, Saraceno G, Trimarchi F, Benvenga S. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 2013; 43:154-160.
50. Le Couteur DG, Hilmer SN, Glasgow N, et al. Prescribing in older people. Austral Fam Phys 2004; 33:777-781.
51. John-Kalarickal J, Pearlman G, Carlson HE. New medications which decrease levothyroxine absorption. Thyroid 2007; 17:763-765. (Pubitemid 350194737)
52. Liwampo L, Hershamn J. Conditions and drugs interfering with thyroid hormone absorption. Best Pract Res Clin Endocrinol 2009; 23:781-792.
53. Barbesino G. Drugs affecting thyroid function. Thyroid 2010; 20:763-770.
54. Benvenga S, Ruggeri RM, Trimarchi F, Monaco F, editors. Thyroid diseases. Boca Raton: CRC Press; 2012. pp. 469-492.
55. Colucci PH, Seng Yue C, Ducharme M, Benvenga S. A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol 2013; 9:40-47; in press.
56. Makita N, Iiri T. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid 2013; 23:151-159.
57. Diefenbach CS, Gnjatic S, Sabbatini P, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008; 14:2740-2748.
58. Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm 2009; 72:105-110.
59. Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 2006; 354:1787-1795.
60. Sachmechi I, Reich DM, Aninyei M, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract 2007; 13:345-349.
61. Checchi S, Montanaro A, Pasqui L, et al. L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J Clin Endocrinol Metab 2008; 93:465-489.
62. Lahner E, Annibale B, Delle Fave G. Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther 2009; 29:379-386.
63. Radaeli Rde F, Diehl LA. Increased levothyroxine requirement in a woman with previously well controlled hypothyroidism and intestinal giardiasis. Arq Brasil Endocrinol Metab 2011; 55:81-84.
64. Virili C, Bassotti G, Santaguida MG, et al. Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J Clin Endocrinol Metab 2012; 97:E419-E422.
65. Muñoz-Torres M, Varsavsky M, Alonso G. Lactose intolerance revealed by severe resistance to treatment with levothyroxine. Thyroid 2006; 16:1171-1173. (Pubitemid 44864493)
66. Hays MT. Absorption of oral thyroxine in man. J Clin Endocrinol 1968; 28:749-756.
67. Hays MT. Thyroid hormone and the gut. Endocrine Res 1988; 14:203-224.
68. Watts NB, Blevins LS Jr. Endocrinology. JAMA 1994; 271:1666-1668. (Pubitemid 24163212)
69. Rajeshwari SR, Annigeri RG, Shettar SS. Johanson-Blizzard syndrome: a rare case report. JIAOMR 2010; 22:225-228.
70. Hwang CS, Sukalo M, Batygin O, et al. Ubiquitin ligases of the N-end rule pathway: assessment of mutations in UBR1 that cause the Johanson-Blizzard syndrome. PLoS One 2011; 6:e24925.
71. Liu ZF, Zhang ZH, Li M, et al. Report of a case with Johanson-Blizzard syndrome and literatures review. Zhonghua Er Ke Za Zhi 2011; 49:66-69.
72. De Luca F, Trimarchi F, Sferlazzas C, et al. Thyroid function in children with cystic fibrosis. Eur J Pediatr 1982; 138:327-330. (Pubitemid 12041563)
73. Delange F, Dalhem A, Bourdoux P, et al. Increased risk of primary hypothyroidism in preterm infants. J Pediatr 1984; 105:462-469. (Pubitemid 14072138)
74. Depasse C, Chanoine JP, Casimir G, Van Vliet G. Congenital hypothyroidism and cystic fibrosis. Acta Paediatr Scand 1991; 80:981-983.
75. Mc Laughlin AM, Crotty TB, Egan JJ, et al. Amyloidosis in cystic fibrosis: a case series. J Cyst Fibros 2006; 5:59-61. (Pubitemid 43137163)
76. Yahiaoui Y, Jablonski M, Hubert D, et al. Renal involvement in cystic fibrosis: diseases spectrum and clinical relevance. Clin J Am Soc Nephrol 2009; 4:921-928.
77. Samuels MH, Thompson N, Leichty D, Ridgway EC. Amyloid goiter in cystic fibrosis. Thyroid 1995; 5:213-215.
78. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 2010; 11:41-50.
79. Rubio IG, Galrão AL, Santo MA, et al. Levothyroxine absorption in morbidly obese patients before and after Roux-En-Ygastric bypass (RYGB) surgery. Obes Surg 2012; 22:253-258.
80. Gkotsina MI, Michalaki MA, Mamali I, et al. Improved LT4 pharmacokinetics after bariatric surgery. Thyroid 2013; 23:414-419.
81. Benvenga S, Toscano A, Rodolico C, et al. Endocrine evaluation for muscular pain. J Roy Soc Med 2001; 94:405-407.
82. Fonseca V, Thomas M, Katrak A, et al. Can urinary thyroid hormone loss cause hypothyroidism? Lancet 1991; 338:475-476.
83. Junglee NA, Scanlon MF, Rees DA. Increasing thyroxine requirements in primary hypothyroidism: don't forget the urinalysis! J Postgrad Med 2006; 52:201-203.
84. Benvenga S. Errors based on units of measure. Lancet 2004; 363:1368. (Pubitemid 38529878)
85. Dagan A, Cleper R, Krause I, et al. Hypothyroidism in children with steroidresistant nephrotic syndrome. Nephrol Dial Transplant 2012; 27:2171-2175.
86. Park SJ, Shin JI. Complications of nephrotic syndrome. Korean J Pediatr 2011; 54:322-328.
87. Afroz S, Khan AH, Roy DK. Thyroid function in children with nephrotic syndrome. Mymensingh Med J 2011; 20:407-411.
88. Trouillier S, Delè vaux I, Rancé N, et al. Nephrotic syndrome: don't forget to search for hypothyroidism. Rev Med Intern 2008; 29:139-144.
89. Chandurkar V, Shik J, Randell E. Exacerbation of underlying hypothyroidism caused by proteinuria and induction of urinary thyroxine loss: case report and subsequent investigation. Endocr Pract 2008; 14:97-103.
90. De Luca F, Gemelli M, Pandullo E, et al. Changes in thyroid function tests in infantile nephrotic syndrome. Horm Metab Res 1983; 15:258-259. (Pubitemid 13092298)
91. Trimarchi F, Gemelli M, Benvenga S, et al. Transient congenital hypothyroidism in an infant with congenital nephrosis of Finnish type. Acta Paediatr Scand 1983; 72:145-147. (Pubitemid 13191981)
92. Surks MI, Schadlow AR, Stock JM, Oppenheimer JH. Determination of iodothyronine absorption and conversion of L-thyroxine (T4) to L-triiodothyronine (T3) using turnover rate techniques. J Clin Invest 1973; 52:805-811.
93. Jauk B, Mikosch P, Gallowitsch HJ, et al. Unusual malabsorption of levothyroxine. Thyroid 2000; 10:93-95. (Pubitemid 30090371)
94. Tönjes A, Karger S, Koch CA, et al. Impaired enteral levothyroxine absorption in hypothyroidism refractory to oral therapy after thyroid ablation for papillary thyroid cancer: case report and kinetic studies. Thyroid 2006; 16:1047-1051. (Pubitemid 46141308)
95. Damle N, Bal C, Soundararajan R, et al. A curious case of refractory hypothyroidism due to selective malabsorption of oral thyroxine. Indian J Endocrinol Metab 2012; 16:466-468.
96. Walter-Sack I, Clanget C, Ding R, et al. Assessment of levothyroxine sodium bioavailability. Recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures. Clin Pharmacokinet 2004; 43:1037-1053. (Pubitemid 39602017)
97. Koythcev R, Lauschner R. Bioequivalence study of levothyroxine tablets compared to reference tablets and an oral solution. Arzneimittelforschung 2004; 54:680-684. (Pubitemid 39422846)
98. Saraceno G, Vita R, Trimarchi F, Benvenga S. A liquid formulation of L-thyroxine (L-T4) solves problems of incomplete normalization/suppression of serum TSH caused by proton pump inhibitors (PPI) on conventional tablet formulations of L-T4. 15th International & 14th European Congress of Endocrinology (ICE/ECE 2012), 5-9 May 2012, Florence. Endocrine Abstracts 2012; 29 (P1626, abstract).
99. Vita R, Saraceno G, Trimarchi F, Benvenga S. In patients with no interference on the intestinal absorption of L-T4 caused by gastro-intestinal disorders or drugs, a liquid formulation of L-T4 permits to reach target TSH levels that were missed by the conventional tablet formulation. 36th Annual Meeting of The European Thyroid Association, 8-12 September 2012, Pisa. Eur Thyroid J 2012; 1:125 (P73, abstract)
100. Santaguida M, Virili C, Del Duca S, et al. Softgel capsules of levothyroxine in the treatment of patients with gastric disorders. 15th International & 14th European Congress of Endocrinology (ICE/ECE 2012), 5-9 May 2012, Florence. Endocrine Abstracts 2012; 29 (P1665, abstract)
101. Vita R, Benvenga S. A case of L-T4 malabsorption caused by a proton pump inhibitor and solved by a novel formulation of L-T4. 94th Annual meeting of The Endocrine Society, 23-26 June 2012, Houston, abstract MON-402